Inovelon rufinamide regulatory update

Eisai submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) for rufinamide as an adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome (LGS). Eisai markets the triazole derivative for patients >4 years in Europe as Inovelon and in the U.S. as Banzel. Rufinamide is also approved for patients >4 years in Switzerland and Canada. ...